Apart from a drug produced in rabbits, 2010 was in some ways an unremarkable year for biologic drugs coming onto the market. Emphasis on safety may be keeping the reins on new product registrations for some time to come. Jim Kling reports.
This is a preview of subscription content, log in via an institution to check access.
References
Schellekens, H. Drug Discov. Today 14, 495–499 (2009).
Simonet, W.S. et al. Cell 89, 309–319 (1997).
Elvidge, S. Nat. Biotechnol. 29, 4 (2011).
Kantoff, P.W. et al. N. Engl. J. Med. 363, 411–422 (2010).
Anonymous. Business Wire, 25 November 2010. http://www.businesswire.com/news/home/20101125005169/en/Research-Markets-Competitor-Analysis---Interleukin-6-IL-6
Pollock, A. The New York Times, 2 August 2009. http://www.nytimes.com/2009/08/03/health/policy/03gout.html?_r=2
Moran, N. Nat. Biotechnol. 28, 1139–1140 (2010).
Adachi, K. & Chiba, K. Perspect. Medicin. Chem. 1, 11–23 (2007).
Brinkmann, V. et al. Nat. Rev. Drug Discov. 9, 883–897 (2010).
Fox, J. Nat. Biotechnol. 28, 1141–1142 (2010).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kling, J. Fresh from the biologic pipeline—2010. Nat Biotechnol 29, 197–200 (2011). https://doi.org/10.1038/nbt.1793
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1793
- Springer Nature America, Inc.
This article is cited by
-
Genome editing revolutionize the creation of genetically modified pigs for modeling human diseases
Human Genetics (2016)
-
Bringing rigour to translational medicine
Nature Reviews Neurology (2014)
-
Reinventing clinical trials
Nature Biotechnology (2012)
-
Industry access to the literature
Nature Biotechnology (2011)